Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a, Multi-center, Double-blind, Placebo-controlled Study Evaluating ABI-H0731+ Entecavir vs Entecavir Alone for the Treatment of Viremic HBeAg-positive Patients With Chronic Hepatitis B

Trial Profile

A Phase 2a, Multi-center, Double-blind, Placebo-controlled Study Evaluating ABI-H0731+ Entecavir vs Entecavir Alone for the Treatment of Viremic HBeAg-positive Patients With Chronic Hepatitis B

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Jan 2019

At a glance

  • Drugs ABI-H0731 (Primary) ; Entecavir (Primary)
  • Indications Hepatitis B
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Assembly Biosciences
  • Most Recent Events

    • 07 Jan 2019 According to an Assembly Biosciences media release, data from the study will be presented at scientific conferences this year.
    • 07 Jan 2019 According to an Assembly Biosciences media release, at the end of six months, patients from this study have the opportunity to rollover to an open label study [NCT03780543]. Interim results are expected during Q2 of 2019.
    • 07 Jan 2019 Status changed from recruiting to active, no longer recruiting, according to an Assembly Biosciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top